Clinical variants of lesions of the nervous system in ANCA-associated vasculitis
DOI: https://doi.org/10.29296/25877305-2022-04-01
Issue:
4
Year:
2022
Systemic vasculitis (SV) is a group of diseases united by the presence of inflammation of the vascular wall. Neurological manifestations may occur at the onset of SV or at the stage of multiple organ damage. Diagnosis of central and peripheral nervous system lesions in ANCA-associated vasculitis is based on neurological examination data and the results of laboratory and instrumental research methods.
Keywords:
neurology
rheumatology
systemic vasculitis
ANCA-associated vasculitis
Wegener’s granulomatosis
microscopic polyangiitis
eosinophilic granulomatosis with polyangiitis Churg–Strauss
multiple mononeuropathy
distal symmetrical polyneuropathy
References:
- Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2016; 3 (3): 122–33. DOI: 10.5152/eurjrheum.2015.0043
- Nataraja A., Mukhtyar C., Hellmich B. et al. Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol. 2007; 21 (4): 713–32. DOI: 10.1016/j.berh.2007.01.004
- Novikov P.I., Moiseev S.V. British Rheumatological Society/British Association of Rheumatology guidelines for the treatment of ANCA-associated vasculitis in adults. Clinical pharmacology and therapy. 2014; 23 (5): 97–104 (in Russ.).
- Moog P., Eren O., Witt M. et al. Assessment of autonomic function in a cohort of patients with ANCA-associated vasculitis. Clin Auton Res. 2016; 26 (4): 279–85. DOI: 10.1007/s10286-016-0364-8
- Greco A., De Virgilio A., Rizzo M.I. et al. Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches. Autoimmun Rev. 2015; 14 (9): 837–44. DOI: 10.1016/j.autrev.2015.05.005
- Choi H.A., Lee M.J., Chung C.S. Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis. J Neurol. 2017; 264 (4): 724–32. DOI: 10.1007/s00415-017-8416-0
- Grygiel-Górniak B., Limphaibool N., Perkowska K. et al. Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018; 130 (7): 581–96. DOI: 10.1080/00325481.2018.1503920
- Fragoulis G.E., Lionaki S., Venetsanopoulou A. et al. Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. Clin Rheumatol. 2018; 37 (3): 737–47. DOI: 10.1007/s10067-017-3835-y
- Lutalo P.M., D’Cruz D.P. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014; 48–49 :94–8. DOI: 10.1016/j.jaut.2014.01.028
- Morozumi S., Koike H., Tomita M. et al. Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol. 2011; 70 (5): 340–8. DOI: 10.1097/NEN.0b013e3182172290
- Chung S.A., Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am. 2010; 36 (3): 545–58. DOI: 10.1016/j.rdc.2010.04.003
- Karras A. Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy. Semin Respir Crit Care Med. 2018; 39 (4): 459–64. DOI: 10.1055/s-0038-1673387
- Nakamoto K., Saraya T., Ogawa Y. et al. Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018; 139: 101–5. DOI: 10.1016/j.rmed.2018.05.003
- Novikov P.I., Semenkova E.N., Moiseev S.V. Modern nomenclature of systemic vasculitis. Clinical pharmacology and therapy. 2013; 33 (1): 70–4 (in Russ.).
- Smith R.M., Jones R.B., Jayne D.R. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012; 14 (2): 210. DOI: 10.1186/ar3797
- Vaglio A., Buzio C., Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013; 68 (3): 261–73. DOI: 10.1111/all.12088
- André R., Cottin V., Saraux J.L. et al. French Vasculitis Study Group (FVSG). Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. Autoimmun Rev. 2017; 16 (9): 963–9. DOI: 10.1016/j.autrev.2017.07.007
- Lepse N., Abdulahad W.H., Kallenberg C.G. et al. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev. 2011; 11 (2): 77–83. DOI: 10.1016/j.autrev.2011.08.002
- Nishi R., Koike H., Ohyama K. et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology. 2020; 94 (16): 1726–37. DOI: 10.1212/WNL.0000000000009309
- Koike H., Sobue G. Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol. 2013; 17 (5): 683–5. DOI: 10.1007/s10157-012-0767-3
- Geetha D., Jefferson J.A. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020; 75 (1): 124–37. DOI: 10.1053/j.ajkd.2019.04.031
- Takeuchi H., Kawasaki T., Shigematsu K. et al. Neutrophil extracellular traps in neuropathy with anti-neutrophil cytoplasmic autoantibody-associated microscopic polyangiitis. Clin Rheumatol. 2017; 36 (4): 913–7. DOI: 10.1007/s10067-017-3546-4
- Graf J. Central Nervous System Disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. Rheum Dis Clin North Am. 2017; 43 (4): 573–8. DOI: 10.1016/j.rdc.2017.06.006
- Radice A., Bianchi L., Sinico R.A. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev. 2013; 12 (4): 487–95. DOI: 10.1016/j.autrev.2012.08.008
- Hansrivijit P., Trongtorsak A., Gadhiya K.P. et al. Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression. Clin Rheumatol. 2021; 40 (7): 2843–53. DOI: 10.1007/s10067-021-05589-8
- Strizhakov L.A., Moiseev S.V., Kogan E.A. et al. Cardiac involvement in systemic vasculitides: Pathogenetic mechanisms, the importance of risk factors for cardiovascular events, and diagnosis. Ter Arkh. 2014; 86 (12): 35–42 (in Russ.).
- Moiseev S.V., Novikov P.I., Meshkov A.D. et al. ANCA-associated vasculitides: classification, diagnosis, assessment of activity and treatment. Clinical pharmacology and therapy. 2014; 23 (1): 44–50 (in Russ.)